Fluoropyrimidine-associated cardiotoxicity: Revisited

Expert Opinion on Drug Safety

Volumn 8, Issue 2, 2009, Pages 191-202

  Saif, M Wasif ^a   Shah, Manasi M ^b   Shah, Anuj R ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIDGEPORT HOSPITAL   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

5 FU; Angina; Arrhythmia; Breast cancer; Capecitabine; Cardiotoxicity; Colon cancer; Fluoropyrimidines; Myocardial infarction; Pancreatic cancer

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CISPLATIN; CORONARY VASODILATING AGENT; CREATINE KINASE; FLUOROURACIL; FOLINIC ACID; LACTATE DEHYDROGENASE; LEVAMISOLE; METHOTREXATE; MITOMYCIN; NITRATE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; VASODILATOR AGENT;

AGE DISTRIBUTION; ANGINA PECTORIS; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONTINUOUS INFUSION; CORONARY ARTERY SPASM; CREATINE KINASE BLOOD LEVEL; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG RECHALLENGE; DRUG REEXPOSURE; DRUG SAFETY; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; ENZYME BLOOD LEVEL; ESOPHAGUS CANCER; GASTROINTESTINAL TUMOR; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPOTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG EDEMA; LUNG EMBOLISM; MEDIASTINUM; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PATIENT MONITORING; PERICARDITIS; PHARMACOGENETICS; PROPHYLAXIS; REPRODUCIBILITY; REVIEW; RISK FACTOR; SEX RATIO; SIDE EFFECT; SMOKING; ST SEGMENT; SYSTEMATIC REVIEW; T WAVE; THORAX PAIN; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; HEART DISEASE; NEOPLASM;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM CHANNEL BLOCKERS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HEART DISEASES; HUMANS; LEUCOVORIN; NEOPLASMS; RISK FACTORS; VASODILATOR AGENTS;

EID: 66949158016     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330902733961     Document Type: Review

References (116)

1. Grem JL. 5-Fluorouracil: forty-plus and still ticking: a review of its preclinical and clinical development. Invest New Drugs 2000;18:299-313 (Pubitemid 30778060)
2. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol 1998;16(1):301-308
3. Malet-Martino M, Martino R. Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review. Oncologist 2002;7(4):288-323 (Pubitemid 34919955)
4. Hosokawa A, Yamada Y, Shimada Y, et al. Weekly Hepatic Arterial Infusion of 5-Fluorouracil and Subsequent Systemic Chemotherapy for Liver Metastases from Colorectal Cancer. Jpn J Clin Oncol 2003;33:132-135 (Pubitemid 43102868)
5. Oman M, Lundqvist S, Gustavsson B, et al. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. Cancer Chemother Pharmacol 2005;56(6):603-609 [Epub 2005 Jul 27] (Pubitemid 41425056)
6. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19(8):2282-2292 (Pubitemid 32366981)
7. Labianca R, Beretta G, Clerici M, et al. Fraschini P, Luporini G. Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982;68:505-510
8. Patel B, Kloner RA, Ensley J, et al. 5-Fluorouracil cardiotoxicity: left ventricular dysfunction and effect of coronary vasodilators. Am J Med Sci 1987;294:238-243 (Pubitemid 18032767)
9. Collins C, Weiden PL. Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 1987;71:733-736
10. Spasojevic I, Zakrzewska J, Bacic GG. 31P NMR spectroscopy and polarographic combined study of erythrocytes treated with 5-fluorouracil: cardiotoxicity-related changes in ATP, 2,3-BPG, and O2. Ann NY Acad Sci 2005;1048:31-120
11. de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992;10(11):1795-1801 (Pubitemid 23059959)
12. Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: A critical review. Ann Oncol 1990;1:409-414 (Pubitemid 20356788)
13. Thyss A, Falewee MN, Leborgne L, et al. Cardiotoxicite du 5-fluoro-uracile: spasme ou toxicite myocardique directe? Bull Cancer (Paris) 1987;74:381-385
14. Milano G, Etienne MC, Pierrefite V, et al. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999;79(3-4):627-630 (Pubitemid 29046246)
15. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006;5(11):2895-2904 (Pubitemid 44849017)
16. Tsavaris N, Kosmas C, Vadiaka M, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy - a survey of 427 patients. Med Sci Monit 2002;8(6):PI51-7 (Pubitemid 34694658)
17. Labianca R, Luporini J. 5-flurouracil cardiotoxicity: risk of rechallenge. Ann Oncol 1991;2:383
18. Lenaz L, Page JA. Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat Ret 1976;3:111-120
19. de Forni M, Armand JP. Cardiotoxicity of chemotherapy. Curr Opin Oncol 1994;6(4):340-344 (Pubitemid 24213570)
20. Fajardo LF, Stewart JR. Pathogenesis of radiation-induced myocardial fibrosis. Lab Invest 1973;29:244-255
21. Anand AJ. Fluorouracil Cardiotoxicity. Ann Pharmacother 1994;28:374-378
22. May D, Wandl U, Becher R, et al. Kardinale nebenwirkungen von 5-fluorouracil. Dtsch Med Wochenschr 1990;115:618-621
23. Pottage A. Holt S, Ludgate S, Langlands AO. Fluorouracil cardiotoxicity. BMJ 1978;1:547 (Pubitemid 8318918)
24. Ensley J, Kish J, Tapazoglou E, et al. 5-fluorouracil infusions associated with an ischemic cardiotoxicity syndrome. Proc Am Soc Gin Onco1 1986; 5:142
25. Kosmos C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008;134(1):75-82 [Epub 2007 Jul 17] (Pubitemid 350060687)
26. Schober C, Papageorgiou E, Harstrick A, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993;72(7):2242-2247 (Pubitemid 23280155)
27. Van Custem E, Hoff PM, Blum JL, et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002;13(3):484-485 (Pubitemid 34705014)
28. Jensen SA, Sørensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 2006;58(4):487-493 (Pubitemid 43999797)
29. Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005;41(11):1542-1546 (Pubitemid 40981835)
30. Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol 2008;6(1):41-48 (Pubitemid 351227868)
31. Kikuchi K, Majima S, Murakami M. Clinical survey on cardiotoxicity of tegafur (FT-207)-compilation of a nationwide survey. Gan To Kagaku Ryoho 1982;9(8):1482-1488
32. Eskilsson J, Albertsson M. Failure of preventing 5-flurouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 1990;29(8):1001-1003
33. Praga C, Beretta G, Labianca R. Cardiac toxicity from antitumor therapy. Oncology 1980;37:51-58 (Pubitemid 11203533)
34. Akpek G, Hartshorn KL. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report. Cancer Chemother Pharmacol 1999;43(2):157-161 (Pubitemid 29045034)
35. Yang TS, Wang JY, Tang R, et al. Oral Uracil/Ftorafur (UFT) Plus Leucovorin as First-line Chemotherapy and Salvage Therapy with Weekly High-dose 5-Fluorouracil/Leucovorin for the Treatment of Metastatic Colorectal Cancer, Japanese. J Clin Oncol 2002;32:352-357 (Pubitemid 43102788)
36. Takimoto C, Lu ZH, Zhang R, et al. Severe Neurotoxicity following 5-Fluorouracil-based Chemotherapy in a Patient with Dihydropyrimidine Dehydrogenase Deficiency. Clin Cancer Res 1996;2:477-481 (Pubitemid 26100049)
37. van Groeningen CJ, Peters GJ, Pinedo HMCJ. Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine. Ann Oncol 1993;4(4):317-320 (Pubitemid 23139373)
38. Popov I, Carrato A, Sobrero A, et al. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). Eur J Cancer 2008;44(15):2204-2211
39. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75(1):11-17
40. Lang-Stevenson D, Mikhailidis DP, Gillet DS. Cardiotoxicity of 5-f1uorouracil [letter]. Lancet 1977;2:406-407
41. Levillain R. Lesion cardiaque observees en microscopie optique chez le rat Wistar apres ingestion de 5-fluorouracile. Journal de Mdecine Besan~on 1972;8:37-44
42. Liss RH, Chadwick M. Correlation of 5-fluorouracil (NSC- 19893) distribution in rodents with toxicity and chemotherapy in man. Cancer Chemother Rep 1974;58:777-786
43. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, et al. Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol 2006;305-309 (Pubitemid 44064964)
44. Rezkalla S, Kloner RA, Ensley J, et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989;7:509-514 (Pubitemid 19098146)
45. Satoh H, Hashimoto K. Effects of ftorafur and 5-fluorouracil on the canine sinoatrial node. Jpn J Pharmacol 1983;33(2):357-362
46. Millart H, Brabant L, Loenzato M, et al. The effects of 5-fluorouracil on cotracility and oxygen uptake of the isolated perfused rat heart. Anticancer Res 1992;12(2):571-576
47. Millart H, Kantelip JP, Platonoff N, et al. Increased iron content in rat myocardium after 5-fluorouracil chronic administration. Anticancer Res 1993;13(3):779-783 (Pubitemid 23216983)
48. Takimoto CH, Tan YY, Cadrnan EC, Armstrong RO. Correlation between ribosomal RNA production and RNA-directed fiuoropyrimidine cytotoxicity. Biochem Pharmacol 1987;36:3243-3248 (Pubitemid 17161012)
49. Spasojevic I, Maksimovic V, Zakrzewska J, Bacic G. Effects of 5-fluorouracil on erythrocytes in relation to its cardiotoxicity: membrane structure and functioning. J Chem Inf Model 2005;45(6):1680-1685
50. Spasojevic I, Zakrzewska J, Bacic GG. 31P NMR spectroscopy and polarographic combined study of erythrocytes treated with 5-fluorouracil: cardiotoxicity-related changes in ATP, 2, 3-BPG, and O2 metabolism. Ann NY Acad Sci 2005;1048:311-320
51. Lemaire L, Malet-Martino MC, de Forni M, et al. Cardiotoxicity of commercial 5-fluorouracil vials stems from alkaline hydrolysis of this drug. Br J Cancer 1992;66(1):119-127
52. Arellano M, Malet-Martino M, Martino R, Gires P. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer 1998;77(1):79-86 (Pubitemid 28029776)
53. Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-f1uorouracil in the guinea pig. Jpn J Pharmacol 1980;30:871-879 (Pubitemid 11162895)
54. 31P-topical nuclear magnetic resonance (31P-TMR) studies of cardiotoxic effects of 5-f1uorouracil (5-FU) and 5′-deoxy-5 fluorouridine (5′-OFUR). Jpn Pharmacol 1984;34:375-379
55. Freeman N, Costanza ME. 5-Fluorouracil-associated cardiotoxicity. Cancer 1988;61:36-45
56. Porta C, Moroni M, Ferrari S, Nastasi G. Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. Neoplasma 1998;45(2):81-82 (Pubitemid 28247448)
57. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 1990;65(4):885-889 (Pubitemid 20063490)
58. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol 2003;42(4):304-308 (Pubitemid 36851147)
59. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. Scanning 2001;23(1):1-8 (Pubitemid 32655510)
60. Dent R, McColl I. 5-fluorouracil and angina. Lancet 1975;1:347-348
61. Baker WP, Dainer P, Lester WM, et al. Ischemic chest pain after 5-fluorouracil therapy for cancer. Am J Cardiol 1986;57:497-498 (Pubitemid 16119733)
62. Raina A, Ferrante F, Bisol A, et al. Cardiotoxicity during chemotherapy for advanced gastroenteric tumors. Tumori 1987;73:359-361 (Pubitemid 17158353)
63. Manegold C, Thomas H, Richter C. Angina pectoris wahrend lokoregionarer Chemotherapie von Lebermetastasen. Dtsch Med Wochenschr 1987;112:2008
64. Jakubowski AA, Kemeny N. Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluororacil. Cancer 1988;62:266-269 (Pubitemid 18172590)
65. Millward MJ, Ganju V, Buck M. Cardiac arrest: a manifestation of 5-fluorouracil cardiotoxicity. Aust NZ J Med 1988;18:693-695 (Pubitemid 19042813)
66. Coronel B, Madonna O, Mercatello A, et al. Myocardiotoxicity of 5 fluorouracil. Intensive Care Med 1988;14:429-430 (Pubitemid 18172129)
67. Oleksowicz L, Bruckner HW. Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. Am J Med 1988;85:750-751 (Pubitemid 19015747)
68. Chaudari S, Song SYT, Jaski BE. Profound, yet reversible heart failure secondary to 5-fluorouracil. Am J Med 1988;85:454-456 (Pubitemid 18231380)
69. Thyss A, Milano G, Schneider M, Demard F. Circulating drug levels in patients presenting cardiotoxicity to 5-FU. J Cancer Res Clin Onco1 1988;24:1675-1676 (Pubitemid 18252635)
70. Cristofini P, Desnos M, Guenot O, et al. Cardiotoxicite du .5-fluoro-uracile: spasme coronaire? Apropos de 2 observations avec coronarographie normale. Ann Med Interne (Paris) 1989;140:9-13 (Pubitemid 19155307)
71. Glaser E, Luquel L, Thomas O, Larminat JM. Fibrillation ventriculaire d'evolution favorable au cours d'une perfusion de fiuorouracile. Presse Med 1989;18:359-360 (Pubitemid 19068526)
72. McKendall GR, Shurman A, Anamur M, Most AS. Toxic cardiogenic shock associated with infusion of 5-fluorouracil. Am Heart 1989;118:184-186 (Pubitemid 19183600)
73. Misset B, Escudier B, Leclercq B, et al. Acute myocardiotoxicity during 5-fluorouracil therapy. Intensive Care Med 1990;16:210-211 (Pubitemid 20226778)
74. Clavel M, Simeone P, Grivet B. Toxicite cardiaque du 5-fluorouracile: revue de la litterature, cinq nouveaux cas. Presse Med 1988;17:1675-1678
75. Villani F, Guindani A, Pagoni A. 5-fluorouracil cardiotoxicity. Tumori 1979;65:487-495
76. Leone B, Rabinovich M, Ferrari CR, et al. Cardiotoxicity as a result of 5-fluorouracil therapy. Tumori 1985;71:55-57 (Pubitemid 15113659)
77. Burger AJ, Mannino S. 5-fluorouracil-induced coronary vasospasm. Am Heart J 1987;114:433-436 (Pubitemid 17131742)
78. Monk MR, Sanchez JD, Phelps CD, Miller DM. Myocardial ischemia with fluorouracil and floxuridine therapy. Clin Pham 1987;6:659-661 (Pubitemid 17137222)
79. Segalini G, Labianca R, Beretta GD, et al. Cardiotossicita da 5-fluorouracile: casistica personale e revisione della letteratura. G Ital Cardiol 1987;17:781-785 (Pubitemid 18001118)
80. Nekliudova VI, Seregin GI, Shkhvatsabaia LV. Cardiotoxic effects of cytostatics in patients with breast cancer [abstract]. Vopr Onko1 1985;31:50-57
81. Ota K. Continuous venous infusion in cancer chemotherapy [abstract]. Gan To Kagaku Ryoho 1985;12:798-805
82. Lee JS, Dhingra HM, Chiuten DF, et al. Phase II pilot study with cisplatin, etoposide, and continuous-infusion fluorouracil in metastatic non-small cell lung cancer. Am J Clin Onco1 1987;10:512-514 (Pubitemid 18000024)
83. Paccagnella A, Pappagallo GL, Segati R, et al. Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck. Am J Clin Onco1 1991;13:194-198 (Pubitemid 20247659)
84. Mandel EM, Lewinski U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer 1975;36:1979-1982
85. Ghione M. Cardiotoxic effect of antitumor agents. Cancer Chemother Pharmacol 1978;1:25-34
86. Somers G, Abramov M, Wittek M, Naets JP. Myocardial infarction: a complication of vincristine treatment? [letter]. Lancet 1976;2:690
87. Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Onco1 1982;9:23-33
88. Yancey RS, Talpaz M. Vindesine-associated angina and ECG changes [letter]. Cancer Treat Rep 1982;66:587-589 (Pubitemid 12084961)
89. Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 1978;62:873-879 (Pubitemid 8377881)
90. O'Connell TX, Berenbaum MC. Cardiac and pulmonary effects of high dose cyclophosphamide and ifosfamide. Cancer Res 1974;34:1586-1591
91. Mills BA, Roberts RW. Cyclophosphamide-induced cardiomyopathy. Cancer 1979;43:2223-2226
92. Eskilsson J, Albertsson M, Mercke C. Adverse effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil. Radiother Onco1 1988;13:41-46 (Pubitemid 18226045)
93. Soukop M, McYie JG, Calman KC. Fluorouracil cardiotoxicity, [letter]. BMJ 1978;1:1422
94. Sullivan RD, Young CW, Miller E, et al. The clinical effect of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-2′-deoxy-uridine). Cancer Chemother Rep 1960;8:77-83
95. Ansfield FJ, Schroeder JM, Curreri AR. Five years clinical experience with 5-fluorouracil. JAMA 1962;181:85-89
96. Carlson RW, Sikic BL. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med 1983;99:823-833 (Pubitemid 14248413)
97. Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity: the role of Krebs cycle inhibition by fiuoroacetate. Arch Neuro1 1970;23:155-160
98. Martin M, Diaz Rubio E, Funo V, et al. Lethal cardiac toxicity after cisplatin and 5-fluorouracil chemotherapy. Am Clin Onco1 1989;12:229-234
99. Carpenter ME. Intravenous fluorouracil and tachycardia [letter]. BMJ 1972;4:595
100. Dent R, McColl I. 5-fluorouracil and angina. Lancet 1975;1:347-348
101. Manente P, Buchberger R, Valmachino G, et al. Cardiotossicita da 5-fluorouracile: descrizione di un caso clinico. Tumori 1980;66:255-260 (Pubitemid 10005331)
102. Gamucci T, Zampa G. Cardiotoxicity of 5-fluorouracil. Tumori 8 1980;66:635-636 (Pubitemid 11215246)
103. Antonelli D, Beker B, Barzilay J. Precoce cardiotossicita da 5- fluorouracile. G Ital Cardiol 1981;11:1758-1761
104. Sanani S, Spaulding MB, Masud ARZ, Canty R. 5-FU cardiotoxicity. Cancer Treat Rep 1981;65:1123-1125 (Pubitemid 12237751)
105. Vorobiof DA. Cardiotoxicity of 5-fluoro-uracil. S Afr Med J 1982;61:634-635
106. Beretta G, Labianca R, Montinari F, Luporini G. Antitumor chemotherapy after 5-fluorouracil angina. J Cancer Res Clin Oncol 1982;104:321-322
107. Underwood D, Groppe C, Tsai A, et al. Coronary insufficiency and 5-fluorouracil therapy: a case report, review and suggestions regarding mechanism. Cleve Clin f Med 1983;50:29-31
108. Pinelli G, Lusa AM, Salvarani R, et al. Esiste una cardiotossicita da 5-fluorouracile? Minerva Cardioangiol 1984;32:627-630
109. Baker WP, Dainer P, Lester WM, et al. Ischemic chest pain after 5-fluorouracil therapy for cancer. Am J Cardiol 1986;57:497-498 (Pubitemid 16119733)
110. Blijham GH, Fiolet HH, van Deijk WA, et al. Angina pectoris associated with infusions of 5-FU and vindesine. Cancer Treat Rep 1986;70:314-315 (Pubitemid 16166190)
111. Manusco L, Bondi F, Marchi S, et al. Cardiac toxicity of 5-fluorouracil: report of a case of spontaneous angina. Tumori 1986;72:l21-4 (Pubitemid 16132302)
112. Escudier B, Alexandre JB, Leclercq B, et al. Cardiotoxicite du 5 fluorouracile: caracteristiques, mechanisme, conduite pratique. Presse Med 1986;15:1819-1821 (Pubitemid 16002266)
113. Sponzilli C, Toff W. Fluorouracil and angina. BMJ 1987;294:125
114. Kleiman NS, Lehane DE, Geyer CE, et al. Prinzmetal's angina during 5-fluorouracil chemotherapy. Am f Med 1987;82:566-568
115. Cunningham D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br J Cancer 1998;77(Suppl 2):15-21 (Pubitemid 28140593)
116. Köhne CH, Thuss-Patience P, Friedrich M, et al. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. Br J Cancer 1998;77(6):973-977 (Pubitemid 28101788)